Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR

Yanzheng Zou(Nanjing Medical University), Peng Huang(Jinling Institute of Technology), Sheng Yang(University of Michigan), Ming Yue(Jiangsu Province Hospital), Yifan Wang(The University of Texas MD Anderson Cancer Center), Meiling Zhang(Zhejiang Cancer Hospital), Hongbo Chen(Jiangsu University), Yidi Wang(Zhongshan People's Hospital), Yue Feng(Hainan Medical University), Rongbin Yu(Ministry of Education), Linna Jia(Nanjing Medical University)
Journal of Hepatocellular Carcinoma
December 1, 2022
10.2147/jhc.s389874
Cited by 9

Related Papers

Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
|Cell|2022|376
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
|Journal of Clinical Investigation|2016|107
Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study
|PLoS ONE|2021|68
Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia
|Frontiers in Medicine|2021|63
Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer
|Theranostics|2020|60